Novo Nordisk
OMA 2026: Oral GLP-1 showdown: Wegovy edges out Foundayo
1200 x 720
Clinical takeaway: Oral semaglutide may offer an efficacy and tolerability advantage among oral GLP-1 options, but results are indirect and should not replace head-to-head data.
An indirect treatment comparison evaluated oral semaglutide 25 mg vs. orforglipron 36 mg using data from separate phase 3 trials (OASIS 4 and ATTAIN-1), addressing a key clinical question in the absence of head-to-head studies.
Oral semaglutide was associated with greater weight loss, with a mean difference of −3.2%. Tolerability also favored semaglutide: orforglipron had about 4x higher odds of discontinuation due to any adverse event and about 14x higher odds due to gastrointestinal events.
In a separate preference study of 800 adults, 84% favored a semaglutide-like profile, suggesting alignment between clinical outcomes and patient preference. Most respondents (65%) reported that fasting dosing requirements would not disrupt daily life. The lack of food and water restrictions is a differentiator for Foundayo.
Novo Nordisk will present this data at the upcoming Obesity Medicine Association annual conference in San Diego, CA on April 10-12.